Core Viewpoint - Micron Robotics-B (02252) has achieved a significant milestone with the approval of its bronchoscopic surgical robot, UniPathTM, by the National Medical Products Administration (NMPA), marking a breakthrough in the field of surgical robotics and expanding its product offerings to seven approved surgical robots [1] Group 1: Company Developments - The stock price of Micron Robotics-B surged by 13.58% to HKD 24.08, with a trading volume of HKD 109 million [1] - The approval of UniPathTM represents a comprehensive coverage of key technological pathways in minimally invasive diagnosis and treatment for domestic surgical robots [1] - Micron Robotics-B is now the first and only company globally to commercialize products across all five major categories of surgical robots [1] Group 2: Product Details - UniPathTM is a non-invasive robotic surgical platform that utilizes a highly flexible, ultra-thin snake-like robotic catheter to access hard-to-reach narrow lesions through natural body cavities [1] - The platform is significant for the early diagnosis and treatment of early-stage cancers, such as small nodules in the lungs [1]